These inhibitors effectively mimic the α-helix structure of p53 in solution or in vivo, occupying the binding pocket, inhibiting Mdm2 activity, and releasing p53, which ultimately restores or enhances p53’s tumor-suppressive function. Here, TP53 is linked to neoplasm.